Cerecor Announces Positive Initial Phase 1b Results for CERC-002 in Moderate to Severe Crohn’s Disease PatientsJuly 26th, 2021|Cell and Gene Therapy, Innovation, Regional News Roundup|Comments Off on Cerecor Announces Positive Initial Phase 1b Results for CERC-002 in Moderate to Severe Crohn’s Disease Patients A biopharmaceutical company announced the results of a Phase 1b of CERC-002.Article from GlobeNewswireShare This Story, Choose Your PlatformFacebookTwitterLinkedInPinterestEmail Related Posts Stories From Our Region – November 2022 HHS Secretary Becerra Joins U.S. Senator Casey for Visit with Leaders in Greater Philadelphia’s Life Sciences Ecosystem Stories From Our Region – October 2022 “Why Greater Philadelphia Ranks #2 As CGT Hub” Featured in Cell & Gene Stories From Our Region – Late September 2022
